Literature DB >> 2969259

Tolerance of spironolactone.

B R Hughes1, W J Cunliffe.   

Abstract

A survey of 54 patients taking spironolactone for hirsutes or acne showed that side-effects occurred in 91%; in 80% of patients, these were related to the anti-androgenic mechanism of the drug (menstrual disturbances, and breast enlargement and tenderness). The concomitant use of a contraceptive pill gave a lower incidence of menstrual abnormalities. Only seven patients (13%) had to stop the drug. In a further eight patients, a reduction in dose to between 125 and 175 mg daily achieved a compromise of controlling the disease and the side-effects. Side-effects tended to occur early and so regular review during the initial 3 months of treatment is advised. Two patients in our study developed 'chloasma'--a previously unreported complication of spironolactone. This was the only side-effect which occurred late in treatment.

Entities:  

Keywords:  Acne; Androgens; Biology; Contraception; Contraceptive Methods; Demographic Factors; Dermatitis; Dermatological Effects; Diseases; Endocrine System; Enzyme Inhibitors--side effects; Enzymes And Enzyme Inhibitors; Family Planning; Hirsutism; Hormone Antagonists; Hormones; Melanosis; Melasma; Menstruation Disorders; Oral Contraceptives; Physiology; Population; Population Characteristics; Sex Factors; Signs And Symptoms; Treatment--side effects

Mesh:

Substances:

Year:  1988        PMID: 2969259     DOI: 10.1111/j.1365-2133.1988.tb02571.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

Review 1.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 2.  Current views on the aetiology, pathogenesis and treatment of acne vulgaris.

Authors:  L Lever; R Marks
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience.

Authors:  Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

4.  Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration.

Authors:  Yu Wang; Shari R Lipner
Journal:  Int J Womens Dermatol       Date:  2020-05-19

5.  Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia.

Authors:  Rehab Nabil Shamma; Mona Hassan Aburahma
Journal:  Int J Nanomedicine       Date:  2014-11-26

Review 6.  Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.

Authors:  Alison M Layton; E Anne Eady; Heather Whitehouse; James Q Del Rosso; Zbys Fedorowicz; Esther J van Zuuren
Journal:  Am J Clin Dermatol       Date:  2017-04       Impact factor: 7.403

7.  The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.

Authors:  Hui Pei; Wei Wang; Di Zhao; Lei Wang; Guo-Hai Su; Zhuo Zhao
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 8.  Female pattern alopecia: current perspectives.

Authors:  Lauren L Levy; Jason J Emer
Journal:  Int J Womens Health       Date:  2013-08-29

Review 9.  Mineralocorticoid receptor antagonists.

Authors:  Hari Krishnan Parthasarathy; Thomas M MacDonald
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

10.  Spironolactone for the treatment of acne in women, a retrospective study of 110 patients.

Authors:  J W Charny; J K Choi; W D James
Journal:  Int J Womens Dermatol       Date:  2017-03-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.